Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
If you need support, reach out to us
Talk to your GP about hormones For some women, addressing the hormonal root cause is the most effective approach
Others: Roche, J&J, Sanofi, and AZ have had GLP-1 efforts (some deprioritized) or new dual/triple agonists in development (e.g., Roches pipeline includes a dual agonist announced in 2024)
2018 updated European league against rheumatism evidence-based recommendations for the diagnosis of gout
You can also use insurance to pay for your medication, if it's covered
Nice concise review that includes all currently FDA appoved antiobesity medications Obesity pharmacotherapy: approvals and major trial readouts (1999-2025) is very useful I also like a quick comparison table of different medications To view or add a comment, sign in Structure Therapeutics' aleniglipron shows promising weight loss results in Phase II trial aleniglipron Structure Therapeutics obesity Structure Therapeutics' investigational oral GLP-1 candidate, aleniglipron, demonstrated over 11% weight loss in a Phase II trial, leading to a nearly 103% increase in the company's stock price
US$ 23.62
US$ 26.65
US$ 22.15
US$ 24.14
US$ 20.51
